Attend the Second Webinar on MRAs and DKD Managementjbrown
Connect with us on October 5 from 3-4.15 p.m. for the second webinar in the series examining the results of the FIGARO-DKD study and assessing its implications for clinical practice in nephrology and cardiology:
Amplification of the presentation of the main results of the FIGARO trial
Join Speakers Gerasimos Filippatos, Greece, Javed Butler, USA, and Adeera Levin, Canada, for the talks:
- Trial design and main results of efficacy and safety
- A conversation between a cardiologist and a nephrologist
A Q&A session will follow these talks.
Register for the session and submit your questions here.
The session will be moderated by Masaomi Nangaku (Japan) and David Wheeler (ISN – ACT Chair) (UK)
FIGARO-DKD was a randomized, double-blind, placebo-controlled, parallel-group, event-driven Phase III study investigating finerenone versus placebo in patients with CKD and T2D.
The study demonstrated that finerenone significantly reduced the composite risk of time to the first occurrence of cardiovascular (CV) death or non-fatal CV events (myocardial infarction, stroke, or hospitalization for heart failure).
This webinar is supported by an unrestricted educational grant from